Epidemiology and outcomes of primary pediatric lung malignancies: Updates from the SEER database. Am J Surg 2021 Oct;222(4):861-866
Date
02/08/2021Pubmed ID
33549297Pubmed Central ID
PMC8985451DOI
10.1016/j.amjsurg.2021.01.037Scopus ID
2-s2.0-85100386252 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
BACKGROUND: Primary pediatric lung malignancies are rare tumors. We provide an updated analysis of the epidemiology and prognosis of these tumors since the last SEER series published in 2009.
METHODS: The SEER 18 database from 1975 to 2016 was analyzed for patients ages 0-19 years with primary lung and/or bronchus neoplasms.
RESULTS: 348 patients met inclusion criteria. The majority were white and ≥12 years of age. The most common histologies were neuroendocrine (41.4%) and blastoma (16.4%). 75.4% of patients had local-regional disease and 81.4% underwent surgery. Significant differences between histologies were seen for age, year at diagnosis, tumor laterality and location, stage, and treatment type. Median survival was 36.6 years (95% CI 33.3-37.4). Blastoma (HR 3.47) and squamous cell (HR 6.26) carried a significantly higher risk of death than neuroendocrine cancer diagnosis.
CONCLUSION: Primary pediatric lung malignancies are rare, long-term survival is favorable but histology-dependent. Surgery continues to be an important treatment modality.
Author List
Smith NJ, Mukherjee D, Wang Y, Brazauskas R, Nelson AA, Cortina CSAuthors
Ruta Brazauskas PhD Associate Professor in the Institute for Health and Equity department at Medical College of WisconsinChandler S. Cortina MD Assistant Professor in the Surgery department at Medical College of Wisconsin
Ariel Nelson MD Assistant Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdolescentChild
Child, Preschool
Demography
Female
Humans
Lung Neoplasms
Male
Neoplasm Staging
Prognosis
SEER Program
Survival Rate
United States
